GF Fund Management CO. LTD. Has $20.17 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

GF Fund Management CO. LTD. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,801 shares of the biopharmaceutical company's stock after acquiring an additional 759 shares during the period. GF Fund Management CO. LTD.'s holdings in Regeneron Pharmaceuticals were worth $20,169,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Moody Aldrich Partners LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $207,000. First Horizon Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 16.1% during the first quarter. First Horizon Advisors Inc. now owns 15,314 shares of the biopharmaceutical company's stock worth $9,713,000 after purchasing an additional 2,119 shares during the period. Novem Group increased its holdings in shares of Regeneron Pharmaceuticals by 31.1% during the first quarter. Novem Group now owns 1,361 shares of the biopharmaceutical company's stock worth $863,000 after purchasing an additional 323 shares during the period. Private Trust Co. NA increased its holdings in shares of Regeneron Pharmaceuticals by 13.1% during the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after purchasing an additional 19 shares during the period. Finally, FSM Wealth Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 17.9% during the first quarter. FSM Wealth Advisors LLC now owns 356 shares of the biopharmaceutical company's stock worth $226,000 after purchasing an additional 54 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on REGN. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research note on Friday, April 25th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Finally, Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $822.58.

Regeneron Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ:REGN traded down $9.25 during mid-day trading on Monday, reaching $538.11. 959,668 shares of the company's stock were exchanged, compared to its average volume of 907,598. The firm has a market capitalization of $58.09 billion, a price-to-earnings ratio of 13.70, a PEG ratio of 2.00 and a beta of 0.33. The business's fifty day moving average price is $549.38 and its 200-day moving average price is $624.74. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the firm posted $9.55 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.65%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.